


(original)

## PATENT CLAIMS

1. Use of glucocorticoid receptor antagonists with a relative binding affinity for the glucocorticoid receptor bond between 85% and 155% of that of dexamethasone and with a relative binding affinity for the progesterone receptor bond between 1% and 11% of that of progesterone or with a 14-fold to 150-fold dissociation between the two receptor types, for the production of a drug for the prophylaxis and therapy of glucocorticoid-mediated hypogonadism, sexual dysfunctions and/or infertility.

(original)  
2. 11 $\beta$ -Substituted steroids as glucocorticoid receptor antagonists of general formula (I)



wherein

R<sub>1</sub> is a methyl, methoxy or ethoxy group and

R<sub>2</sub> is a tert.butyl group, sec.propyl alcohol or sec. propyl ether or a substituted benzene ring.

(original)  
3. 11 $\beta$ -Substituted steroids according to Claim 2,  
namely

21-tert.butyl-17-hydroxy-11 $\beta$ -(3-methoxyphenyl)-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-3-one,  
methyl-4-{17-hydroxy-11 $\beta$ -[3-(methoxy)phenyl]-3-keto-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-21-yl)}  
benzoate,

3-{17-hydroxy-11 $\beta$ -[3-(methoxy)phenyl]-3-keto-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-21-yl)}benzaldehyde,

4-{17-hydroxy-11 $\beta$ -[3-(methoxy)phenyl]-3-keto-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-21-yl)}

phenylacetate,

17-hydroxy-11 $\beta$ -[3-(methoxy)phenyl]-21-(4-pyrrolyl)phenyl-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-3-one,

17-hydroxy-21-(4-hydroxyphenyl)-11 $\beta$ -[3-(methoxy)phenyl]-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-3-one,

17-hydroxy-21-(4-mesylphenyl)-11 $\beta$ -(3-methoxyphenyl)-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-3-one,

21-tert.butyl-17-hydroxy-11 $\beta$ -(3-ethoxyphenyl)-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-3-one,

21-(4-tert.butylphenyl)-17-hydroxy-11 $\beta$ -(3-methoxyphenyl)-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-3-one,

ethyl(E)-3-[17-hydroxy-11 $\beta$ -(3-methoxyphenyl)-3-keto-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-21-yl)} isocrotonate,

21-(3,5-difluorophenyl)-17-hydroxy-11 $\beta$ -(3-methoxyphenyl)-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-3-one,

21-(2-trifluorophenyl)-17-hydroxy-11 $\beta$ -(3-methoxyphenyl)-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-3-one,

21-(3,5-dimethylphenyl)-17-hydroxy-11 $\beta$ -(3-methoxyphenyl)-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-3-one,

4-{17-hydroxy-11 $\beta$ -[3-(methoxy)phenyl]-3-keto-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-21-yl)} phenylsulfamate,

17-hydroxy-21-(1-hydroxy-1-methylethyl)-11 $\beta$ -(3-methoxyphenyl)-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-3-one,

3-(17-hydroxy-3-keto-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-11 $\beta$ -yl)benzaldehyde,

(E)-3-[17-hydroxy-11 $\beta$ -(3-methoxyphenyl)-3-keto-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-21-yl)benzaldoxime,

17-hydroxy-21-(1-methoxy-1-methylethyl)-11 $\beta$ -(3-methoxyphenyl)-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-3-one,

17-hydroxy-21-(4-mesylphenyl)-11 $\beta$ -(3-methylphenyl)-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-3-one,

17-hydroxy-21-(4-mesyloxyphenyl)-11 $\beta$ -(3-methylphenyl)-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-3-one, and

4-{17-hydroxy-11 $\beta$ -[3-methylphenyl]-3-keto-19-nor-17 $\alpha$ -pregna-4,9-dien-20-yn-21-yl}

phenylaminoacetate.

*(currently amended)*

4. Use of 11 $\beta$ -substituted steroids as glucocorticoid receptor antagonists according to ~~Claims 2 and 3~~ *Claim 2* for producing a drug for the prophylaxis and therapy of glucocorticoid-mediated hypogonadism, sexual dysfunctions and/or infertility.

*(currently amended)*

5. Use of glucocorticoid receptor antagonists according to ~~Claims 1 to 4~~ *Claim 1*, characterized in that

the administration occurs orally, subcutaneously, sublingually, in the form of an inhalator or as a plaster, ointment or gel.

*(currently amended)*

*Claim 1*

6. Use of glucocorticoid receptor antagonists according to ~~Claims 1 to 5~~ for producing a drug, characterized in that the daily dose to be administered is from 0.01 mg to 100 mg per body weight [sic].